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Abstract
BACKGROUND AND PURPOSE—Patients with SAH are at increased risk of delayed 
infarction. Early detection and treatment of delayed infarction remain challenging. We assessed 
blood-brain barrier permeability, measured as permeability surface area product, by using CTP in 
patients with SAH with delayed infarction.
MATERIALS AND METHODS—We performed a retrospective study of patients with SAH 
with delayed infarction on follow-up NCCT. CTP was performed before the development of 
delayed infarction. CTP data were postprocessed into permeability surface area product, CBF, and 
MTT maps. Coregistration was performed to align the infarcted region on the follow-up NCCT 
with the corresponding location on the CTP maps obtained before infarction. Permeability surface 
area product, CBF, and MTT values were then obtained in the location of the subsequent 
infarction. The contralateral noninfarcted region was compared with the affected side in each 
patient. Wilcoxon signed rank tests were performed to determine statistical significance. Clinical 
data were collected at the time of CTP and at the time of follow-up NCCT.
RESULTS—Twenty-one patients with SAH were included in the study. There was a statistically 
significant increase in permeability surface area product in the regions of subsequent infarction 
compared with the contralateral control regions (P < .0001). However, CBF and MTT values were 
not significantly different in these 2 regions. Subsequent follow-up NCCT demonstrated new 
delayed infarction in all 21 patients, at which time 38% of patients had new focal neurologic 
deficits.
CONCLUSIONS—Our study reveals a statistically significant increase in permeability surface 
area product preceding delayed infarction in patients with SAH. Further investigation of early 
permeability changes in SAH may provide new insights into the prediction of delayed infarction.
Aneurysmal subarachnoid hemorrhage is a devastating illness with an average case fatality 
rate of 51% and approximately one-third of survivors needing life-long care.1 Patients who 
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survive are at high risk for developing sequelae of cerebral vasospasm and delayed cerebral 
ischemia (DCI), leading to delayed infarction, which occurs in 40%–70% of patients with 
SAH, representing the leading cause of post-SAH morbidity and mortality.2 Recent studies 
reported a dissociation of angiographic vasospasm and poor neurologic outcome, supporting 
the assumption that infarction rather than vasospasm might reflect the ultimate end point of 
different proischemic pathomechanisms, including microvascular and neuronal 
dysfunction.3
Early and delayed microcirculatory dysfunction after SAH is increasingly thought to be 
associated with DCI resulting in delayed infarction, in the absence of proximal vasospasm.4 
Microvascular dysfunction can be assessed by using CTP. CTP parameters currently used in 
clinical practice are MTT, CBF, and CBV,5 which provide useful findings regarding the 
presence and extent of DCI.5–10 However, screening tools are lacking for earlier detection of 
patients at particularly high risk of developing delayed infarction from DCI to prompt 
therapeutic pre-emptive measures to minimize the impending morbidity and mortality. 
Currently, the assessment of patients with SAH for DCI relies primarily on clinical 
examination, transcranial Doppler sonography, and NCCT. Clinical examination is limited 
because symptoms can be variable and difficult to detect,11 while transcranial Doppler 
sonography is limited by poor sensitivity and specificity.12–14 Although NCCT can detect 
delayed infarction, the management and treatment goals in patients with SAH are to prevent 
these sequelae of DCI.
Blood-brain barrier permeability (BBBP) is known to increase in certain conditions such as 
ischemia, malignancy, infection, and autoimmune disease.15 On the molecular level, the 
BBB is composed of the neurovascular unit, comprising tight junctions between astrocytes 
and vascular endothelial cells. Permeability surface-area product (PS), derived from CTP, 
measures the diffusion of contrast from the vascular into the interstitial space, thus providing 
an indirect measure of BBBP.16 Although several reports describe the high sensitivity and 
specificity of the CTP-derived CBF and/or MTT to detect perfusion abnormalities in 
DCI,5,7–10,17,18 alterations of the BBBP have not yet been studied in this context.
We hypothesized that BBBP increases before delayed infarction in patients with SAH. The 
purpose of this study was to assess whether alterations in BBBP, measured as PS by using 
CTP, precede development of infarction related to DCI after SAH.
MATERIALS AND METHODS
Study Population
A retrospective analysis was performed on consecutive patients with SAH enrolled in a 
prospective diagnostic accuracy trial at our institution. SAH was determined by a 
combination of NCCT, CTA, DSA, and/or CSF analysis. In this prospective study design, 
CTP was performed during the baseline period on days 0–3 following aneurysmal rupture 
with day zero defined as the day of the initial hemorrhagic event, to assess baseline cerebral 
perfusion and to compare it with later perfusion examinations for interval change. A follow-
up CTP was performed on the day of new focal neurologic deficits or on days 6–8 in 
asymptomatic patients. Institutional review board approval was obtained.
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In our study, inclusion criteria were the following: 1) patients with delayed infarction related 
to DCI detected on NCCT, and 2) CTP, including assessment of PS performed before 
infarction. Follow-up NCCT was obtained as a standard of care at our institution to assess 
complications of SAH, including repeat hemorrhage, hydrocephalus, and new infarction.
Patients with SAH were classified as having DCI according to published criteria from recent 
expert consensus,19 consisting of a radiologic and clinical component. These criteria 
included either a new infarction on CT or MR imaging within 6 weeks after SAH or clinical 
manifestations of new focal neurologic impairment or a decrease of at least 2 points on the 
Glasgow Coma Scale. Regions of delayed infarction were defined as new areas of ischemia 
not present on imaging up to 48 hours after aneurysm occlusion and not attributable to other 
causes such as surgical clipping, endovascular treatment, ventricular catheter placement, and 
intraparenchymal hematoma.19 This definition has been used to effectively exclude primary 
brain damage from SAH and/or surgical interventions.19 Delayed infarction was dictated in 
the clinical reports of the NCCT by board-certified neuroradiologists on service at our 
institution. A second independent board-certified neuroradiologist blinded to all clinical and 
imaging data confirmed the presence and exact location of the infarcted region in each case 
for inclusion in this study.
Exclusion criteria were the following: 1) patients with an infratentorial infarction, given that 
the posterior fossa is not adequately imaged on CTP; and 2) severe motion degradation 
limiting CTP postprocessing.
Data collection included detailed review of each patient’s clinical chart and recording of 
each patient’s demographic characteristics, clinical symptoms at presentation, aneurysm 
location, clinical symptoms at the time of CTP and NCCT, infarction location, and modified 
Rankin Scale clinical outcome score. Subsequently, these clinical data were grouped and 
analyzed across all 21 patients.
CTP Image Acquisition, Postprocessing, and Analysis
Routine NCCT was performed from the foramen magnum to the vertex by using the 
following parameters: 120 kV(peak), 250 mAs, 1.0 rotation time, and 5.0-mm collimation. 
Extended CTP to measure PS was performed on a LightSpeed Discovery 750 64-section 
scanner (GE Healthcare, Milwaukee, Wisconsin) by using axial shuttle mode with the 
following parameters: 80 kVp, 400 mAs, 0.4 rotation time, 5.0-mm collimation with 17 cine 
cycles and 2.8-second interscan delay for the first pass. The second-pass technique included 
10 cine cycles with a 10-second interscan delay. A total of 90 mL of nonionic contrast was 
intravenously administered at 4.0 mL/s followed by a 30-mL saline bolus.
All CTP data were postprocessed by using CT Perfusion 4D software (GE Healthcare) for 
generation of PS, CBF, and MTT maps. PS represents the flow across the blood vessel wall, 
from the intravascular space to the extravascular extracellular space, and thus constitutes a 
measure of BBBP. Its units are milliliter × milliliter−1 × minute−1 (volume of liquid per 
volume of tissue per minute). PS measurements are derived from the tail of the tissue 
attenuation curve obtained after the first pass of contrast. In normal cerebral vasculature, PS 
is negligible.20
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The follow-up NCCT showing the delayed infarction was used for ROI placement within the 
exact infarct location. Using the symmetry tool in AW2 software (GE Healthcare), we 
generated a “mirror ROI” in the corresponding location on the contralateral side of the brain 
to serve as the control for each patient. Figure 1A illustrates the ROI placement in a 
representative patient.
Using the integrated registration tool in the AW2 software, we performed coregistration of 
the preinfarction CTP, and corresponding follow-up NCCT was performed in 3 planes for 
each patient. Integrated registration enabled propagation of the ROIs in the regions of 
subsequent infarction and the contralateral control from each follow-up NCCT onto the 
respective CTP maps obtained before infarction. Figure 1B illustrates coregistration of the 
NCCT from Fig 1A with the preinfarction CTP. CBF, MTT, and PS values were then 
measured within the ROI in the regions of subsequent infarction and the contralateral 
control. Statistical analysis included Wilcoxon signed rank tests for each CTP parameter to 
determine whether statistically significant differences in CTP parameter means (with 95% 
confidence intervals) were present between the regions of subsequent infarction and 
contralateral controls.
RESULTS
Clinical Characteristics of the Study Population
Twenty-one patients with SAH with 23 delayed infarctions in the anterior circulation were 
included in the analysis. Patients were excluded if they had infratentorial infarctions (n = 1) 
or if severe motion artifacts impeded CTP postprocessing (n = 2). The mean age was 50 
years (range, 35–88 years) with 76% (16/21) women and 76% (16/21) with anterior 
circulation aneurysms. The mean Hunt and Hess score at presentation was 3. NCCT 
performed at the time of the CTP examination did not demonstrate infarction in any of the 
patients included in this study. The median day for performing CTP after aneurysmal 
rupture was day zero (range, 0–3 days, with 71% [15/21] of patients undergoing their CTP 
on day 0 of admission). At the time of the preinfarction CTP, only 10% (2/21) of patients 
had developed new focal neurologic deficits not present on their admission clinical 
examination, while the remaining 90% (19/21) of patients had an unchanged clinical 
examination compared with their admission status. Follow-up NCCT demonstrated a new 
infarction at 4 days after CTP (range, 1–7 days) with 91% (21/23) MCA infarctions and 9% 
(2/23) anterior cerebral artery infarctions. By the time the NCCT showed the infarction, 38% 
(8/21) of patients exhibited new focal neurologic deficits. The median modified Rankin 
Scale score at the time of discharge was 3 (range, 0–6), indicating moderate disability.
CTP Analysis
There was a statistically significant increase in PS in the region of subsequent infarction on 
the preinfarction CTP, compared with the contralateral control region (Table) in 96% of 
infarctions (22/23). Figure 2 demonstrates the consistency of elevated PS before infarction 
across the entire study population. However, no significant difference was seen for CBF and 
MTT between the regions of subsequent infarction and contralateral controls (Table). Figure 
3 demonstrates PS elevation preceding the development of subsequent delayed infarction in 
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a representative patient. In addition, the tissue attenuation curves representing the region of 
subsequent infarction and the contralateral control region demonstrate an elevation of the 
tail of the tissue attenuation curve (extended pass) in the region of subsequent infarction (Fig 
3D).
DISCUSSION
Currently, the assessment of patients with SAH for DCI and delayed infarction is 
challenging, given the need to rely on clinical examination, transcranial Doppler 
sonography, and NCCT data to initiate early treatment and prognosticate patient outcomes. 
The value of clinical examination is limited due to the potential subjectivity of symptom 
assessment, low specificity of symptoms, and the frequent incidence of a depressed level of 
consciousness in patients in the intensive care unit, which can limit the performance of 
reliable neurologic examinations.11 Transcranial Doppler sonography is also limited by poor 
sensitivity and specificity.12–14 Thus, there is a strong need for the development and 
validation of novel imaging strategies allowing identification of patients with SAH at high 
risk for delayed infarction.
In this study, we have shown that increased PS assessed by CTP precedes the development 
of delayed infarction seen on NCCT in patients with SAH. These findings were present in 
91% (21/23) of regions of subsequent infarction and were statistically significant across the 
entire study population. Most important, at the time of the preinfarction CTP, the perfusion 
parameters of CBF and MTT (the most sensitive parameters currently available to clinically 
assess perfusion deficits17) were not statistically different in the region of subsequent 
infarction compared with the contralateral control region. Furthermore, only 10% of patients 
manifested new focal neurologic deficits at the time of the preinfarction CTP, suggesting 
that an elevation in PS values could represent an early indicator of subsequent infarction. 
Thus, the detection of BBBP changes may prove a more sensitive method to detect delayed 
infarction related to DCI compared with conventional NCCT and CTP parameters of CBF 
and MTT, and before clinical symptoms. Furthermore, at the time of follow-up NCCT 
demonstrating the subsequent infarction, more patients (38%) had developed new focal 
neurologic deficits. Our findings are similar to those in prior studies reporting the 
development of neurologic deficits in up to 40% of patients with DCI.21,22 Moreover, 
patients with DCI have been shown to have a statistically increased rate of permanent 
deficits and worse clinical outcomes compared with patients without DCI.21,22
The BBB is composed of endothelial cells connected by tight junctions, providing an 
effective barrier against paracellular permeability. Transient or permanent cerebral injury 
can lead to alteration in molecular signaling pathways, such as the ubiquitin-proteasome 
pathway, leading to BBB disruption and degradation of the extracellular matrix, resulting in 
vasogenic edema.23 Experimental data have demonstrated increased BBBP and dysfunction 
of the endothelium and vascular components of the brain associated with the development of 
DCI and poor outcomes in animal models.15 Moreover, a decrease in BBB disruption and an 
associated decrease in the effects of cerebral ischemia were seen in animal models treated 
with novel pharmaceutical agents that stabilize the BBB.24,25 BBBP increase and cerebral 
ischemia thus appear to be closely intertwined; however, understanding the temporal 
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resolution of these 2 pathophysiologic processes remains challenging. In human subjects, 
perfusion CT and MR imaging have been introduced as tools to measure BBBP.16,26
Although significant differences existed in PS values in the regions of subsequent infarction 
versus respective contralateral control regions, our study is limited by its small size and 
retrospective nature. Future studies are needed to establish the clinical value of monitoring 
PS as a predictor of delayed infarction related to DCI and poor outcomes and to compare PS 
values in patients with and without DCI, thus expanding our understanding of the utility of 
PS for prognostication in patients with SAH.
CONCLUSIONS
Our data indicate that the measurement of BBBP using CTP-derived PS has the potential to 
become a significant marker for the prediction of delayed infarction related to DCI before 
the onset of clinical symptoms and before alterations seen in MTT and CBF. Our results 
emphasize the need for continued prospective investigation of BBBP alteration in DCI to 
develop a clinical indicator for prediction and prognosis of SAH-related morbidity and 
mortality. Large prospective studies are needed to further validate these initial findings and 
to provide insight into the underlying pathomechanisms leading to delayed infarction related 
to DCI after SAH. More important, such future investigations could aid in the development 
of new strategies targeting the prevention of delayed infarction after SAH.
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ROI placement and coregistration in a representative patient. A, NCCT of a representative 
patient with SAH demonstrates ROI placement in the region of a new left frontal infarction, 
which was not present on admission (red) and the contralateral control ROI (green). B, 
Coregistration of the NCCT from A with the preinfarction CTP yields matched ROI 
placement on the PS map and the CBF and MTT maps (not shown).
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PS values in the regions of subsequent infarction versus respective contralateral control 
regions for each individual patient.
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CTP performed on day zero of admission in a representative patient with SAH (same patient 
as shown in Fig 1). A, Elevated PS is demonstrated in the left frontal region (circled in red) 
compared with the contralateral side. B, CBF is not significantly different in the same region 
compared with the contralateral side. Follow-up NCCT (C) reveals an infarction in the exact 
location of the increased PS seen 2 days prior in this patient. D, Tissue attenuation curves 
representing the region of subsequent infarction (red) and the contralateral control region 
Ivanidze et al. Page 11









(green) obtained in this patient, demonstrating an elevation of the tail of the tissue 
attenuation curve (extended pass) in the region of subsequent infarction.
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PS (mL × mL−1 × min−1) 0.56 (0.45–0.68) 0.35 (0.25–0.45) <.0001
CBF (mL × 100 g−1 × min−1) 17.22 (14.00–20.43) 17.39 (14.78–20.00) .7048
MTT (sec) 10.85 (8.78–12.92) 10.06 (7.42–12.70) .128
a
Mean values are shown with 95% confidence intervals (in parentheses).
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